Share Market Live: Sensex, Nifty Hold Steady Gains
By Shraddha K
Net profit down 45% YoY at Rs 164.52 crore vs estimate of Rs 223 crore (Bloomberg consensus)
Revenue down 0.7% YoY at Rs 1,326.03 crore vs estimate of Rs 1,259 crore
Ebitda down 39% YoY at Rs 253.98 crore vs estimate of Rs 322 crore Total costs up 17% YoY at Rs 1,145.37 crore
Pranav Amin, Managing Director of Alembic Pharmaceuticals said while the India business grew exceptionally well during the quarter, the U.S. business faced price erosion due to increased competition.
Out of 19 analysts tracking the company, 9 maintained ‘buy’, 6 maintained ‘hold’ and 4 analysts maintained ‘sell’ recommendations. The overall consensus price of analysts tracked by Bloomberg implied an upside of 18%.